Charles Russell Speechlys advises the Business Growth Fund (BGF), on the investment by the BGF in Renal Services
Charles Russell Speechlys has advised the Business Growth Fund on its investment in Renal Services, an independent provider of dialysis services to NHS patients.
Headquartered in London, Renal Services was founded in 2007, employs 62 staff and is the fourth largest provider of dialysis in the UK. The company currently runs six dialysis centres across the UK, operating 63 dialysis stations and treating approximately 700 permanent and transient patients on behalf of the NHS. Approximately 95% of treatments are delivered to permanent local patients.
The centres, which were designed and built by Renal Services, are located in Grantham, Havant, Launceston, Milford on Sea, Salisbury and Skegness. The company manages all aspects of dialysis care at its centres including clinical, quality control, data collection, diagnostics and maintenance services. It puts patient experience, choice and outcomes at the centre of its service with an on-going track record in exceeding local and national standards as set out by the Department of Health and the Renal Association.
Rory Pope of the BGF commented “As always, it was a pleasure to work with Malcolm, Lee and the rest of the Charles Russell Speechlys team. Their service and advice was of the usual highest standards and critical to us completing this investment”.
The Charles Russell Speechlys core team comprised Malcolm MacDougall, Lee Holland and Genevieve Morrall from the Private Equity team, with support from members of our Tax, Intellectual Property, Employment and Real Estate teams. Malcolm MacDougall commented: “We are delighted to have completed another deal for the Business Growth Fund, and to have been involved in Renal Services’ growth plans”.
News & Insights
November - Newsletter - Financial Services Institutions Briefing
Welcome to the latest edition of our Financial Services Institutions Briefing.
Product governance under MiFID II – a UK perspective
Jonathan Bayliss explores product governance under MiFID II, from a UK perspective